A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder

Pharmacological Interventions for Binge Eating: Lessons from Animal Models, Current Treatments, and Future Directions

(2012) Laura A. Berner et al.   CURRENT PHARMACEUTICAL DESIGN

Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals

(2012) Samuel R. Chamberlain et al.   PSYCHOPHARMACOLOGY

Pharmacological management of binge eating disorder: current and emerging treatment options

(2012) Susan McElroy et al.   Therapeutics and Clinical Risk Management

Opioid modulators for alcohol dependence

(2011) Thomas Hillemacher et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial

(2010) Thomas A. Wadden et al.   Obesity

Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats

(2009) Mark S. Todtenkopf et al.   ADDICTION BIOLOGY

The validity and clinical utility of binge eating disorder

(2009) Stephen A. Wonderlich et al.   INTERNATIONAL JOURNAL OF EATING DISORDERS

From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour

(2009) Pradeep J. Nathan et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY